Cartilage repair therapeutics - Histogenics/Intrexon

Drug Profile

Cartilage repair therapeutics - Histogenics/Intrexon

Alternative Names: Induced pluripotent stem cells derived therapeutics - Histogenics/Intrexon; iPSC derrived therapeutics - Histogenics/Intrexon

Latest Information Update: 08 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Histogenics Corporation
  • Developer Histogenics Corporation; Intrexon Corporation
  • Class Cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Cartilage disorders

Most Recent Events

  • 03 Oct 2014 Early research in Cartilage disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top